In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin
- PMID: 1336344
- PMCID: PMC245533
- DOI: 10.1128/AAC.36.12.2709
In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin
Erratum in
- Antimicrob Agents Chemother 1993 Apr;37(4):930
Abstract
Clinical trials with daptomycin were halted in December 1990 because of treatment failures including two resistant Staphylococcus aureus strains. High protein binding of daptomycin (> 90%) and the lower-than-expected concentrations in serum with the dosage regimen of 3 mg/kg of body weight every 12 h may have contributed to these failures. To evaluate the effect that higher concentrations would have on bactericidal activity measured by time-kill curves, peak and trough concentrations were estimated for dosage regimens of 3, 5, and 10 mg/kg every 12 h. MICs, MBCs, and killing curves for daptomycin and vancomycin were performed by using the estimated concentrations with four S. aureus strains obtained from patients who failed daptomycin therapy for endocarditis. MICs and MBCs of daptomycin demonstrated a greater inoculum effect than those of vancomycin; MICs and MBCs of daptomycin increased three- to fourfold, but those of vancomycin increased only one- to twofold when the inoculum was increased from 5 x 10(5) to 5 x 10(7) CFU/ml. No pH-dependent effect on MICs or MBCs was seen. Strenuous experimental conditions were chosen: high inoculums (5 x 10(7) CFU/ml), extremes of pH (6.4, 7.4, and 8), and stationary and exponentially growing organisms; and all experiments completed in the presence of pooled human serum. Daptomycin exhibited concentration-dependent killing and statistically faster kill rates than vancomycin against stationary- or exponential-growth-phase organisms. A pH-dependent decrease in activity with daptomycin was also demonstrated. Daptomycin and vancomycin produced higher kill rates against exponentially growing organisms. A pH-dependent decrease in activity with daptomycin was also demonstrated. Daptomycin and vancomycin produced higher kill rates against exponentially growing organisms. The results indicate that the use of higher dosage regimens with compounds similar to daptomycin may be capable of overcoming the effects of pH, high inoculum, and protein binding.
Similar articles
-
Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.Diagn Microbiol Infect Dis. 1990 May-Jun;13(3):245-52. doi: 10.1016/0732-8893(90)90067-6. Diagn Microbiol Infect Dis. 1990. PMID: 2166634
-
Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.Int J Antimicrob Agents. 2011 Apr;37(4):332-8. doi: 10.1016/j.ijantimicag.2010.12.007. Int J Antimicrob Agents. 2011. PMID: 21388792
-
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72. doi: 10.1128/AAC.48.12.4665-4672.2004. Antimicrob Agents Chemother. 2004. PMID: 15561842 Free PMC article.
-
In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.Antimicrob Agents Chemother. 2000 Jul;44(7):1925-9. doi: 10.1128/AAC.44.7.1925-1929.2000. Antimicrob Agents Chemother. 2000. PMID: 10858356 Free PMC article.
-
Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.Lancet Infect Dis. 2009 Oct;9(10):617-24. doi: 10.1016/S1473-3099(09)70200-2. Lancet Infect Dis. 2009. PMID: 19778764 Review.
Cited by
-
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.Antimicrob Agents Chemother. 2003 Apr;47(4):1318-23. doi: 10.1128/AAC.47.4.1318-1323.2003. Antimicrob Agents Chemother. 2003. PMID: 12654665 Free PMC article. Clinical Trial.
-
Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.Antimicrob Agents Chemother. 2003 Aug;47(8):2538-44. doi: 10.1128/AAC.47.8.2538-2544.2003. Antimicrob Agents Chemother. 2003. PMID: 12878516 Free PMC article.
-
Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.Antimicrob Agents Chemother. 2007 Dec;51(12):4255-60. doi: 10.1128/AAC.00824-07. Epub 2007 Oct 8. Antimicrob Agents Chemother. 2007. PMID: 17923487 Free PMC article.
-
Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.Drugs. 2007;67(10):1483-512. doi: 10.2165/00003495-200767100-00008. Drugs. 2007. PMID: 17600394 Review.
-
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.Antimicrob Agents Chemother. 2001 Feb;45(2):454-9. doi: 10.1128/AAC.45.2.454-459.2001. Antimicrob Agents Chemother. 2001. PMID: 11158740 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases